Yang Wang MD, PhD

Biologist and immunologist with nearly 20 years of industry experience leading discovery research, preclinical, and early clinical development (phase I and II) of biologics. Proven track record in discovery innovation, translational science, CMC leadership, and regulatory success across more than ten biologics programs—including eight INDs and one FDA compassionate use approval. Over 9 years of executive leadership experience, with strong management skills to build and develop R&D laboratories and teams from the ground up across various size companies. Demonstrated history of cross-sector partnerships with academia, industry, NGOs, CROs, CDMOs, and VCs. Inventor and senior author of over 50 publications and U.S. patents on biologics. Comitted mentor and organizational builder.SpecialtiesIn-depth knowledge and expertise in discovery research, preclinical development, IND-enabling studies (PK/PD, toxicology), and IND authoring and filing (Phases I and II) across diverse biological applications and disease indications, including autoimmune, infectious, and neurodegenerative diseases.Strong expertise in GMP-compliant process development, CMC technology transfer and regulatory interaction for biologics. Years of leadership experience overseeing both R&D and CMC efforts as program lead for internal pipelines and external CDMO clients.